These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23126535)

  • 1. Botulinum toxin type A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients.
    Hikita K; Honda M; Kawamoto B; Panagiota T; Inoue S; Hinata N; Muraoka K; Takenaka A
    Int J Urol; 2013 Jan; 20(1):94-9. PubMed ID: 23126535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
    Chen G; Liao L
    Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
    Sengoku A; Okamura K; Kimoto Y; Ogawa T; Namima T; Yamanishi T; Yokoyama T; Akino H; Maeda Y
    Int J Urol; 2015 Mar; 22(3):306-9. PubMed ID: 25403926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
    Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study.
    Baron M; Peyronnet B; Aublé A; Hascoet J; Castel-Lacanal E; Miget G; Le Doze S; Prudhomme T; Manunta A; Cornu JN; Gamé X
    J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
    Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
    J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
    Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
    J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
    Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
    Ghalayini IF; Al-Ghazo MA; Elnasser ZA
    Int Urol Nephrol; 2009 Dec; 41(4):805-13. PubMed ID: 19184509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.
    Koh C; Melling CV; Jennings C; Lewis M; Goyal A
    J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
    Naqvi S; Clothier J; Wright A; Garriboli M
    J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
    Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
    J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
    Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
    J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.
    Grosse J; Kramer G; Stöhrer M
    Eur Urol; 2005 May; 47(5):653-9. PubMed ID: 15826758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
    Abdel-Meguid TA
    J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
    Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
    Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.
    Kaviani A; Khavari R
    Urol Clin North Am; 2017 Aug; 44(3):463-474. PubMed ID: 28716326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.